6-K 1 a6939x.htm RESULT OF AGM a6939x
 
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
Form 6-K
 
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
 
 
 
For the month of May 2021
 
Commission File Number 001-15170
 
 
GlaxoSmithKline plc
(Translation of registrant's name into English)
 
 
980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address of principal executive office)
 
 
 
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
 
Form 20-F . . . .X. . . . Form 40-F . . . . . . . .
 
 
 
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ____
 
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ____
 
 
GlaxoSmithKline plc
 
Results of Annual General Meeting
 
GlaxoSmithKline plc ('GSK') held its Annual General Meeting ('AGM') at 2.30pm on Wednesday 5 May 2021.
 
The statement made by the Chairman at the AGM will shortly be available to view on GSK's website at www.gsk.com.
 
All valid proxy votes (whether submitted electronically or in hard copy form) were included in the poll taken at the meeting.
 
The table below shows the results of the poll on all 22 resolutions. The full text of the resolutions is contained in the Notice of AGM published on 30 March 2021, which is available on GSK's website at www.gsk.com.
 
 
Resolution
Total votes for(1)(2)
%
Total votes against(2)
%
Total votes cast
Votes withheld(3)
1
Receive and adopt the 2020 Annual Report
3,475,135,362
98.81
41,757,734
1.19
3,516,893,096
11,603,440
2
Approve the Annual report on remuneration  
3,272,132,033
93.14
240,932,159
6.86
3,513,064,192
15,444,148
3
Re-election of Sir Jonathan Symonds
3,499,343,831
99.52
16,763,629
0.48
3,516,107,460
12,371,547
4
Re-election of Dame Emma Walmsley
3,507,017,955
99.68
11,159,384
0.32
3,518,177,339
10,359,075
5
Re-election of Charles Bancroft
3,506,975,009
99.74
9,026,131
0.26
3,516,001,140
12,472,435
6
Re-election of Vindi Banga
3,496,064,409
99.43
19,904,292
0.57
3,515,968,701
12,509,463
7
Re-election of Dr Hal Barron
3,507,018,967
99.69
10,733,599
0.31
3,517,752,566
10,738,305
8
Re-election of Dr Vivienne Cox
3,497,451,811
99.46
18,813,391
0.54
3,516,265,202
12,207,081
9
Re-election of Lynn Elsenhans
3,434,728,312
97.69
81,301,678
2.31
3,516,029,990
12,440,783
10
Re-election of Dr Laurie Glimcher
3,508,174,526
99.77
7,947,259
0.23
3,516,121,785
12,353,907
11
Re-election of Dr Jesse Goodman
3,506,872,640
99.74
9,131,605
0.26
3,516,004,245
12,467,159
12
Re-election of Iain Mackay
3,501,889,913
99.56
15,637,087
0.44
3,517,527,000
10,951,129
13
Re-election of Urs Rohner
3,484,061,208
99.10
31,702,634
0.90
3,515,763,842
12,752,529
14
Re-appointment of the auditor
3,512,936,007
99.84
5,521,996
0.16
3,518,458,003
10,024,350
15
Remuneration of the auditor
3,511,280,034
99.82
6,176,678
0.18
3,517,456,712
11,022,183
16
Authority for the company to make donations to political organisations and incur political expenditure
3,440,815,513
98.36
57,276,887
1.64
3,498,092,400
30,393,327
17
Authority to allot shares
3,362,807,250
95.66
152,632,653
4.34
3,515,439,903
13,038,799
18
Disapplication of pre-emption rights - general power(4)
3,368,593,428
95.88
144,660,127
4.12
3,513,253,555
15,222,364
19
Disapplication of pre-emption rights - in connection with an acquisition or specified capital investment(4)
3,291,504,396
93.68
221,978,886
6.32
3,513,483,282
14,999,454
20
Authority for the company to purchase its own shares(4)
3,449,168,275
98.36
57,436,714
1.64
3,506,604,989
21,875,135
21
Exemption from statement of senior statutory auditor's name
3,477,878,016
99.47
18,543,893
0.53
3,496,421,909
31,294,363
22
Authority for reduced notice of a general meeting other than an AGM(4)
3,286,542,818
93.50
228,494,172
6.50
3,515,036,990
12,675,849
 
 
Notes:
 
(1)
 
The "for" votes include those giving the Chairman discretion. In line with the notification issued to American Depositary Receipt (ADR) holders last year, GSK did not instruct its ADR Depositary to vote any unvoted ADRs in respect of the AGM resolutions.
 
(2)
 
Votes "for" and "against" are expressed as a percentage of the total votes cast.
 
(3)
 
A vote withheld is not a vote in law and is not counted in the calculation of the proportion of votes "for" or "against" a resolution.
 
(4)
 
Indicates Special Resolutions requiring a 75% majority.
 
 
 
The following table provides further relevant information:
 
 
 
 
GSK's
Twenty first
AGM
(2021)
 
GSK's
Twentieth
AGM
(2020)
Issued share capital (excluding Treasury Shares)
5,031,444,276
5,017,091,542
Total votes cast and votes withheld lodged as a % of GSK's issued share capital (excluding Treasury Shares)
70.11%
72.60%
Total shareholder population
100,906
105,353
Total number of proxies lodged
6,089
6,268
% of shareholders who lodged proxies
6.03%
5.95%
 
The above poll results will shortly be available on the company's website at www.gsk.com. In accordance with Listing Rule 9.6.2, a copy of the resolutions, other than those concerning ordinary business, will be submitted to the UK Listing Authority and will in due course be available for inspection at https://data.fca.org.uk/#/nsm/nationalstoragemechanism 
 
 
V A Whyte
Company Secretary
 
5 May 2021
 
 
 
SIGNATURES
 
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.
 
GlaxoSmithKline plc
 
(Registrant)
 
 
Date: May 05, 2021
 
 
 
 
By:/s/ VICTORIA WHYTE
--------------------------
 
 
 
Victoria Whyte
 
Authorised Signatory for and on
 
behalf of GlaxoSmithKline plc